|
Today's Headlines
In response to rising compounding drug costs, pharmacy benefit managers, such as Express Scripts, have made moves to restrict their coverage for active ingredients used by compounding pharmacies. » Full article
|
|
Chemotherapy-induced nausea and vomiting (CINV) is among the most feared adverse effects associated with cancer treatment. The likelihood of patients experiencing this entity depends on both patient-related and treatment-related factors. Not all chemotherapeutic products induce equivalent amounts of CINV resulting in the formation of groups contingent on the frequency of CINV in patients receiving a product without antiemetic prophylaxis.
» Full article
|
Continuing Education
This month's article is the sixth in a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. From February 2014 through January 2015, pharmacists can earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.
The goal of this month's activity is to review the pharmacokinetic and pharmacodynamic differences, clinical indications, and pertinent drug-drug interactions for antiplatelet agents in cardiovascular disease.
To read and print the article with TEST QUESTIONS, click here. To proceed to the online exam and earn up to 2 CPE credits, click here to log in with the session code 14DT08-KTF27.
Announcement: Starting this month, our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is
https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/
|
|
|
EDITOR'S PICK
FDA actions in brief, priority review, breakthrough designations, fast-track designations, orphan drug designations, first-time generic approval
» Full article
|
|
Like
Tweet
